A 42-year-old woman with acute leukemia undergoing intensive chemotherapy (day 15 post-induction) develops persistent fever (38.5°C) unresponsive to broad-spectrum antibiotics for 7 days. She has neutrophil count of 120/μL. High-resolution CT chest shows multiple nodules with a 'halo sign' (ground-glass opacity surrounding a nodule). Sputum culture is negative. What is the most likely diagnosis and the drug of choice for treatment?

Explanation

## Diagnosis: Invasive Pulmonary Aspergillosis (IPA) ### Clinical Context **Key Point:** The **halo sign** on HRCT is a pathognomonic early finding in invasive aspergillosis — it represents hemorrhage around a fungal nodule in a severely immunocompromised host. **High-Yield:** Invasive aspergillosis occurs almost exclusively in neutropenic patients (neutrophil count < 500/μL, often < 100/μL). *Aspergillus fumigatus* is the most common cause (~90% of cases). The halo sign appears within the first 2 weeks of infection and indicates active angioinvasion with bleeding. ### Risk Stratification | Risk Factor | Relevance in This Case | | --- | --- | | Acute leukemia | Underlying hematologic malignancy | | Intensive chemotherapy | Profound immunosuppression | | Neutrophil count 120/μL | Severe neutropenia (< 500 = high risk) | | Day 15 post-induction | Peak risk period for fungal infection | | Fever unresponsive to antibiotics × 7 days | Suggests fungal rather than bacterial etiology | | Negative sputum culture | Rules out common bacterial/TB pathogens | **Clinical Pearl:** In a severely neutropenic patient with persistent fever, negative bacterial cultures, and a halo sign on imaging, empiric antifungal therapy should be started immediately — do NOT wait for culture confirmation. ### Radiologic Findings in Invasive Aspergillosis ```mermaid flowchart TD A[Invasive Aspergillosis<br/>Radiologic Evolution]:::outcome A --> B[Early Phase<br/>Day 0-7]:::action B --> C[Halo Sign<br/>Ground-glass + nodule]:::outcome A --> D[Intermediate Phase<br/>Day 7-14]:::action D --> E[Air-crescent Sign<br/>Cavitation + air]:::outcome A --> F[Late Phase<br/>Day 14+]:::action F --> G[Cavitary Lesion<br/>Wedge-shaped infarct]:::outcome ``` **Mnemonic:** **HALO-AIR-CRESCENT** progression: - **H**alo = early hemorrhage (angioinvasion) - **A**ir-crescent = intermediate (cavity formation) - **C**rescent = late (cavitation with air) ### Organism Identification | Feature | *Aspergillus fumigatus* | *Rhizopus* (Mucor) | | --- | --- | --- | | Hyphal morphology | Septate, narrow (2–3 μm) | Non-septate, broad (6–30 μm) | | Branching angle | Acute (45°) | Right angle (90°) | | Angioinvasion | Yes (causes hemorrhage) | Yes (causes necrosis) | | Tissue appearance | Hemorrhagic nodule | Black eschar | | Speed of progression | Subacute (days to weeks) | Acute (hours to days) | | Halo sign | Yes (classic) | No | | Typical host | Neutropenic, transplant | Diabetic, immunocompromised | ### Treatment: First-Line Antifungal Therapy **Key Point:** Liposomal amphotericin B (L-AmB) is the **gold standard** for invasive aspergillosis in neutropenic patients. **Dosing & Monitoring:** - **Induction:** L-AmB 10 mg/kg/day IV - **Duration:** Until clinical improvement + immune reconstitution (neutrophil recovery) - **Monitoring:** Baseline and weekly renal function, electrolytes (especially K⁺, Mg²⁺) - **Switch to voriconazole** after clinical stabilization (better CNS penetration, oral bioavailability) **High-Yield:** Voriconazole is preferred for **maintenance** therapy and has superior CNS penetration if aspergillosis spreads to the brain. However, in acute, severe disease with neutropenia, L-AmB is initiated first. ### Why NOT Other Options? | Option | Why Incorrect | | --- | --- | | Posaconazole | Triazole; used for prophylaxis or maintenance, not acute IPA. Slower onset than L-AmB. | | Meropenem | Broad-spectrum β-lactam; ineffective against fungi. Negative sputum culture rules out bacterial etiology. | | Isoniazid + rifampicin | TB drugs; TB is very rare in acute leukemia patients on chemotherapy. No TB-specific risk factors or imaging findings. | **Warning:** Do NOT delay antifungal therapy waiting for culture results. Galactomannan antigen (serum or BAL) or PCR may support diagnosis, but clinical + radiologic findings are sufficient to start treatment. ### Diagnostic Confirmation 1. **Galactomannan antigen** (serum or bronchoalveolar lavage) — sensitivity ~70% in IPA 2. **Aspergillus PCR** (serum or BAL) — higher sensitivity (~80–90%) 3. **Biopsy** (if accessible) — histology shows septate hyphae with acute-angle branching 4. **Culture** — slow to grow; not reliable for acute diagnosis [cite:Harrison 21e Ch 207; Robbins 10e Ch 8]